Arax Advisory Partners’s Lucid Diagnostics LUCD Stock Holding History
Bought
Maintained
Sold
Other funds holding LUCD
TSC
MCM
Arax Advisory Partners's LUCD Position: Q2 2026 in Review
Arax Advisory Partners increased its Lucid Diagnostics (LUCD) stake by 8,441% in Q2 2026, buying an estimated $10.6K and bringing the position to 9,993 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4296.
Arax Advisory Partners first reported a position in LUCD in Q3 2025 and has held it in 3 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.
- Arax Advisory Partners held 9,993 shares of Lucid Diagnostics worth $10.7K as of Q2 2026.
- Arax Advisory Partners bought 9,876 Lucid Diagnostics shares in Q2 2026, an estimated $10.6K.
- Lucid Diagnostics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4296 holding.
- Arax Advisory Partners first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 3 quarters since.
- 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.